Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLICROSS: Polypill vs Separate Components in Coronary Artery Disease
NCT05030818Phase 4Recruiting
- Sponsor
- EPIC Holdings
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aspirin + atorvastatin + ramipril in coronary artery disease (CAD), sponsored by EPIC Holdings. Started Oct 2022; status: recruiting.
02
Drugs
aspirin + atorvastatin + ramipril
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05030818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030818.